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Germany; and 5Division of Nephrology, University of Maryland School of Medicine, Baltimore, Maryland, USAAutosomal dominant polycystic kidney disease (ADPKD) is
the most common monogenic cause of end-stage renal
disease. The molecular pathogenesis of ADPKD is not
completely known, and there is no approved therapy. To
date, there is limited knowledge concerning the molecular
consequences of speciﬁc disease-causing mutations. Here
we show that the ADPKD missense variant TRPP2D511V
greatly reduces TRPP2 protein stability, and that TRPP2D511V
function can be rescued in vivo by small molecules
targeting the TRPP2 degradation pathway. Expression of
the TRPP2D511V protein was signiﬁcantly reduced compared
to wild-type TRPP2. Inhibition of lysosomal degradation of
TRPP2D511V by the US Food and Drug Administration
(FDA)–approved drug chloroquine strongly increased
TRPP2 protein levels in vitro. The validation of these results
in vivo requires appropriate animal models. However, there
are currently no mouse models harboring human PKD2
missense mutations, and screening for chemical rescue of
patient mutations in rodent models is time-consuming and
expensive. Therefore, we developed a Drosophila
melanogaster model expressing the ortholog of TRPP2D511V
to test chemical rescue of mutant TRPP2 in vivo. Notably,
chloroquine was sufﬁcient to improve the phenotype of
ﬂies expressing mutant TRPP2. Thus, this proof-of-concept
study highlights the potential of directed therapeutic
approaches for ADPKD, and provides a rapid-throughput
experimental model to screen PKD2 patient mutations and
small molecules in vivo.
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Kidney International (2016) 89, 949–955A DPKD is the most common fatal monogenic disease inhumans and a leading cause of end-stage renal disease.The 5-year probability of survival among ADPKD
patients with end-stage renal disease is #40%.1 There is no
approved therapy to cure cystic disease, and current treat-
ments include dialysis and transplantation, which are
burdensome and costly. Mutations in polycystic kidney disease
2 (PKD2) account for approximately 1 in 6 ADPKD cases,
that is, about 2,000,000 cases worldwide. The PKD2 gene
product, transient receptor potential polycystin-2 (TRPP2),
is a nonselective cation channel.2 Several pathogenic missense
mutations that impair TRPP2 ion channel function have been
reported.3,4 The conﬁned impact of a single amino acid
change makes missense mutations attractive candidates for
corrective approaches using small molecules. A successful
example of this strategy is the development of a therapeutic
intervention for cystic ﬁbrosis, which targets a speciﬁc causal
mutation rather than disease symptoms.5 Two classes of drugs
have been developed for cystic ﬁbrosis: (i) correctors, which
target cellular misprocessing of cystic ﬁbrosis transmembrane
conductance regulator (CFTR), the protein mutated in cystic
ﬁbrosis; and (ii) potentiators, which restore CFTR ion chan-
nel activity at the cell surface.6 The approval of ivacaftor by
the FDA for the treatment of patients carrying the rare
CFTR variant G551D highlights the feasibility of personalized
therapies for inherited channelopathies such as cystic ﬁbrosis
and polycystic kidney disease.5 Furthermore, the clinical
use of ivacaftor is continuously expanding to larger pools of
patients based on common pathogenic mechanisms between
G551D and other CFTR missense mutations.7 On the
basis of this paradigm, we hypothesized that the analysis of
allele-speciﬁc pathogenic mechanisms might reveal promising
therapeutic targets for ADPKD. Here we show that the
ADPKD patient missense mutation TRPP2D511V greatly
reduces cellular TRPP2 protein stability and that TRPP2D511V
function can be partially rescued in vivo by an FDA-approved
drug targeting the default TRPP2 degradation pathway.RESULTS
A PKD2missense mutation reduces TRPP2 protein abundance
Aspartate 511 of TRPP2 is highly conserved throughout
evolution (Figure 1a). Non-synonymous substitution of this
aspartate with valine has been reported to eliminate TRPP2
ion channel function in vitro.4,8 We have recently shown that949
Figure 1 | The autosomal dominant polycystic kidney disease missense variant TRPP2D511V reduces TRPP2 protein abundance. (a) The
human TRPP2D511V mutation is localized in the highly conserved third transmembrane segment (TRPP2506–527) of TRPP2. (b) Western blot
analysis of wild-type TRPP2 shows 2 distinct bands.19 Compared to wild-type, TRPP2D511V shows reduced protein levels in HeLa cells. (c) This
effect is not cell type–speciﬁc, because a similar reduction is observed in HEK293T cells. (d) Group data from b and c show a signiﬁcant
reduction of TRPP2D511V protein levels by 85% compared to wild-type TRPP2 in HeLa cells (n ¼ 5; P ¼ 2  10–6), and by 63% in HEK293T cells
(n ¼ 5; P ¼ 3  10–4).
t e chn i ca l no te s A Hofherr et al.: Small-molecule rescue of a PKD2 mutationthis substitution reduces protein abundance and ciliary
localization of TRPP2 in D melanogaster, suggesting a path-
ogenic mechanism involving impaired protein processing in
addition to defective channel gating in vivo.8,9 To test whether
protein expression of human TRPP2D511V protein is also
reduced and to characterize the molecular impact of the
D511V substitution in more detail, we expressed wild-type
and mutant protein in different cell lines. TRPP2D511V
showed a signiﬁcant reduction in protein levels by 85%
compared to wild-type TRPP2 in HeLa cells 48 hours after
transfection (Figure 1b and d). This effect was not cell type–
speciﬁc, because a similar reduction was observed inFigure 2 | TRPP2D511V is temperature-sensitive. (a) mRNA of transiently
mRNA abundance is similar as assessed by quantitative polymerase cha
expression at 27 C in HeLa cells by Western blot. (c) Group data from
950HEK293T cells (–63%) (Figure 1c and d). To ensure that
this decrease was not caused by slower TRPP2 protein pro-
cessing kinetics, we measured TRPP2 levels in HeLa cells
96 hours after transfection and found a similar reduction of
mutant TRPP2 compared to wild-type (mean ¼ –90.6%;
n ¼ 4; P ¼ 0.008). Conceptually, either transcriptional
downregulation or impaired protein processing might
account for these signiﬁcantly reduced TRPP2D511V protein
levels. However, PKD2 mRNA transcription or stability was
not impaired by the D511V mutation, suggesting that
TRPP2D511V reduces TRPP2 protein levels by impairing
protein processing (Figure 2a).transfected HeLa cells was isolated. TRPP2 wild-type and TRPP2D511V
in reaction. (b) Comparison of TRPP2 wild-type and TRPP2D511V
b.
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Figure 3 | TRPP2D511V is degraded in lysosomes. (a) Western blot analysis shows that TRPP2D511V is more abundant in cells treated with
200 mM chloroquine (CQ) compared with control cells. (b) MG-132 (210 mM) does not affect TRPP2D511V protein levels. (c) Group data from a and
b show that chloroquine signiﬁcantly increases abundance of TRPP2D511V (mean ¼ 1461%; n ¼ 4; P ¼ 0.003), whereas MG-132 shows no effect
(mean ¼ 108%; n ¼ 4).
A Hofherr et al.: Small-molecule rescue of a PKD2 mutation t e chn i ca l no te sTRPP2D511V is degraded in lysosomes
Nascent polypeptides, including TRPP2, transit between a
signiﬁcant number of intermediate folding states before
attaining their native state.10 The ﬁdelity of this process can be
compromised by amino acid substitutions.10 Cell cultivation
at reduced temperatures (25 C–35 C) can rescue the ther-
modynamic instability of mutant proteins.11 Thermal stress
triggers the expression of molecular chaperones promoting
protein synthesis, folding, and trafﬁcking.11 We found that
TRPP2D511V is temperature-sensitive, because incubating cells
at 27 C equalized TRPP2 protein levels in wild-type and
TRPP2D511V, akin to temperature-sensitive CFTR mutations
(Figure 2b and c). To investigate the mechanism of TRPP2
protein degradation in more detail, we used small-molecule
inhibitors to target the 2 major cellular proteolytic path-
ways: lysosome- and proteasome-mediated degradation.
Inhibition of lysosomal function with chloroquine signiﬁ-
cantly increased TRPP2D511V protein levels (Figure 3). In
contrast, the proteasomal inhibitor MG-132 had no effect on
TRPP2D511V, although it induced a signiﬁcant accumulation
of ubiquitin-conjugated proteins (mean ¼ 162%; n ¼ 6;
P ¼ 0.002). Taken together, these data suggest that the D511V
mutation compromises TRPP2 folding, thereby promoting
lysosomal degradation.
Chemical rescue of lysosomal degradation
The chemical rescue of TRPP2D511V protein degradation by
the FDA-approved drug chloroquine suggested that it might
be possible to restore mutant TRPP2 function. Since there is
no robust cellular assay of TRPP2 function,12,13 we turned to
a genetically tractable model organism where TRPP2 muta-
tion yields a robust and quantitative phenotype. We have
previously shown that ciliary TRPP2 (Amo) is required for
male fertility in D melanogaster.8,14 In ADPKD patients,
sporadic defects in male fertility have been described.15 In
contrast to homozygous mutant ﬂies, the underlying
mechanism in humans is not understood, as patients are
heterozygous for disease-causing ADPKD mutations.15–17
Amo-deﬁcient D melanogaster males produce motile sperm
that are transferred to the uterus but do not reach the femaleKidney International (2016) 89, 949–955sperm storage organs, which is critical for reproductive
success. We engineered ﬂies carrying the TRPP2D511V patient
mutation to test our hypothesis in vivo. In D melanogaster,
AmoD627V (equivalent to human TRPP2D511V) is a loss-
of-function variant without dominant-negative effects.8 The
male infertility phenotype in amo–/– ﬂies can be completely
rescued by the expression of transgenic Amo (TRPP2)
(Figure 4a).8,14 In contrast, AmoD627V failed to restore normal
numbers of progeny (Figure 4a and b), but was able to slightly
increase the fertility of amo–/– ﬂies, suggesting that this
protein might have some residual function. Notably, feeding
of chloroquine (3 mM) to male amo–/–;amoD627V ﬂies
signiﬁcantly increased fertility by a factor of 3 (Figure 4b). On
the molecular level this correlated with an increase of ﬂagellar
AmoD627V protein expression in sperm (Figure 4c–f).
DISCUSSION
Loss-of-function mutations in TRPP2 result in ADPKD.2
The precise molecular events of how TRPP2 mutations
cause renal cyst formation are still unclear. Currently there are
no therapies targeting the primary defect of ADPKD. For
polycystin-1–dependent ADPKD, however, proteasome
inhibitor therapy has been proposed as an effective thera-
peutic approach.18 We have previously shown TRPP2 is
degraded in lysosomes.19 Here we show that non-
synonymous substitution of aspartate 511 with valine results
in lysosomal degradation of TRPP2. Lysosomal inhibition
is sufﬁcient to elevate the level of mutant TRPP2 protein
and results in a partial rescue of TRPP2 function in vivo.
Our study was inspired by the chemical rescue of speciﬁc
CFTR missense mutations causing cystic ﬁbrosis. The recent
FDA approval of ivacaftor for the treatment of patients
carrying the rare CFTR variant G551D highlights the feasi-
bility of personalized therapies for inherited channelopathies
such as cystic ﬁbrosis and polycystic kidney disease.5 The
efﬁcacy of ivacaftor suggests that it might be worthwhile to
explore similarly targeted corrective therapies for ADPKD.
The ivacaftor success story is remarkable, because human
clinical trials were initiated based solely on efﬁcacy studies in
cell culture since rodent models harboring pathogenic human951
Figure 4 | Chloroquine rescues mutant D melanogaster TRPP2 (Amo) function in vivo. (a) Wild-type (w1118) ﬂies have a large number of
progeny (mean ¼ 251; n ¼ 8), while amo mutant males (amo–/–) are infertile (mean number of progeny ¼ 2.4; n ¼ 8; P ¼ 9  10–11). A third
chromosomal amo transgene in the amo–/– mutant background can rescue the fertility phenotype (amo–/–;amo) (mean number of progeny
¼ 236; n ¼ 8). (b) Introduction of an amoD627V transgene on the third chromosome fails to rescue male infertility of amo–/– males. Feeding of
3 mM chloroquine to amo–/–;amoD627V males, however, signiﬁcantly increases fertility compared to that of untreated ﬂies of the same genotype
(mean number of progeny¼ 20; n ¼ 10; P¼ 0.007). Lower concentrations of chloroquine (0.2 mM) showed no effect, whereas dietary chloroquine
at or above 10 mM caused signiﬁcant toxicity. Please note that the amoD627V transgene causes a small but signiﬁcant increase in male fertility
compared to that of amo–/– males, suggesting residual function of the amoD627V variant (mean number of progeny ¼ 2.4 vs. 7.2, respectively;
n ¼ 10; P ¼ 0.002). In contrast, amo–/– males fed chloroquine have progeny similar to untreated controls (mean number of progeny ¼ 1.3;
n ¼ 10). (c–e) Localization of Amo in mature sperm in wild-type (w1118), amo–/–;amoD627V, and chloroquine-treated amo–/–;amoD627V ﬂies (anti-
Amo: green; bar ¼ 5 mm; n ¼ 8). Chloroquine treatment results in an increase of ﬂagellar Amo expression, without enrichment at the tip of the
sperm tail. Previous studies have shown that Amo localization in amo–/–;amo ﬂies is similar to wild-type.8 (f) Western blot of Amo protein from
male ﬂies of the indicated genotypes. Amo was immunoprecipitated from wild-type (w1118), amo–/–;amoD627V, and chloroquine-treated ﬂies
(3 mM). Amo expression was reduced in amo–/–;amoD627V ﬂies compared to wild-type (w1118) (–76.1%; SD ¼ 12.8; n ¼ 2). Chloroquine treatment
of amo–/–;amoD627V ﬂies increased Amo protein levels (mean ¼ þ40.3%; SD ¼ 16.7; n ¼ 2). Equal numbers of ﬂies were used for all experimental
conditions. Tubulin served as a loading control.
t e chn i ca l no te s A Hofherr et al.: Small-molecule rescue of a PKD2 mutationmutations were not available.7 This was feasible because
CFTR channel function in the plasma membrane can be
reproducibly measured in heterologous expression systems.
Unfortunately, this approach cannot be adapted to the study952of small-molecule rescue of mutant TRPP2 channels, since
there is no robust assay for TRPP2 channel function in
heterologous expression systems. While some investigators
have reported electrophysiological measurements of TRPP2Kidney International (2016) 89, 949–955
A Hofherr et al.: Small-molecule rescue of a PKD2 mutation t e chn i ca l no te schannel function, many groups, including ourselves, have
failed to measure TRPP2 whole cell currents in the plasma
membrane of cells overexpressing the wild-type chan-
nel.4,13,20–22 Furthermore, it has not been possible to
measure TRPP2 ion channel activity in vertebrate cilia or in
D melanogaster sperm to date.13
To overcome the notorious problem of investigating TRPP2
channel function in heterologous expression systems, we used
D melanogaster as a readout for TRPP2 channel function
in vivo. Cilia are thought to be the critical site of action for
TRPP2 channels.16 The ciliary localization and function of
TRPP2 are evolutionarily conserved. The function of TRPP2
patient mutations can be studied in a quantitative fashion
using the robust fertility defect of TRPP2 mutant ﬂies.8,14 Our
results using chloroquine to rescue male infertility show a
small but signiﬁcant rescue of the male infertility in ﬂies
expressing mutant TRPP2. The most likely explanation for the
incomplete rescue of chloroquine-treated ﬂies is a gating
defect of mutant TRPP2 as has been previously reported.4 It is
also possible, however, that the smaller relative increase of
mutant TRPP2 protein levels in D melanogaster as compared
to cell lines is not sufﬁcient for a complete rescue of the
phenotype. Since we cannot measure TRPP2 ion channel
activity in vertebrate cilia or in ﬂy sperm,13 we cannot
completely exclude the possibility that chloroquine has a
salutatory effect on the channel function of mutant TRPP2.
However, since this agent increases the expression of
TRPP2D511V in cultured cells and AmoD627V in ﬂies, the most
parsimonious explanation is that chemical rescue with chlo-
roquine acts primarily by increasing the level of a mutant
protein with some residual channel activity. More efﬁcient
rescue of mutant TRPP2 function will therefore probably
require a combination of corrective drugs such as chloroquine,
acting to increase protein abundance, and potentiating drugs
similar to ivacaftor,5 which increase ion channel activity.
In summary, our data show that targeted corrective ap-
proaches might be feasible in ADPKD. This proof-of-concept
study shows that the function of a speciﬁc TRPP2 patient
missense mutation can be improved in vivo. Non-truncating
missense mutations in the PKD2 gene are found in about
20% of PKD2 patients.17 Since other TRPP2 missense
mutants are processed similarly,19 we propose that targeting
general mechanisms of TRPP2 turnover may have a broader
application. The success story of ivacaftor in the treatment of
cystic ﬁbrosis demonstrates that an agent that was initially
conceived to treat patients with a rare CFTR missense
mutation can be used in a broader subset of patients
harboring other amino acid substitutions.7 Further develop-
ment of corrective therapeutic approaches for ADPKD will
require high-throughput screening of chemical libraries
and characterization of additional patient mutations. To
our knowledge, there are currently no mouse models
harboring speciﬁc human PKD2 mutations, and screening for
chemical rescue of patient mutations in rodent models
is time-consuming and expensive. Alternatively, a 2-stage
hierarchical screening strategy consisting of in vitro analysisKidney International (2016) 89, 949–955of protein processing followed by in vivo modeling of speciﬁc
patient mutations in D melanogaster considerably increases
efﬁciency over testing compounds a priori in mouse models.
This platform may help to identify allele-speciﬁc pathogenic
mechanisms and corrective lead compounds for targeted




Full-length human PKD2 (GenBank: U50928) in pcDNA3
(Invitrogen, Carlsbad, CA) was kindly provided by Feng Qian
(University of Maryland).22 Using this wild-type plasmid,
TRPP2D511V was generated by site-directed mutagenesis.
Antibodies
Anti-TRPP2 (G-20) antibodies were obtained from Santa Cruz
Biotechnology (Dallas, TX). A monoclonal anti-TRPP2 antibody
against amino acid residues 698 to 799 (anti-TRPP2698–799) was
kindly provided by Gerd Walz (Medical Center, University of
Freiburg). Clone AC-15 Anti-b-Actin was purchased from
Sigma-Aldrich (St. Louis, MO). The monoclonal anti-a-tubulin
(AA4.3) antibody developed by C. Walsh was obtained from the
Developmental Studies Hybridoma Bank (National Institute of Child
Health and Human Development). Clone P4D1 anti-ubiquitin
antibodies were purchased from Covance (Princeton, NJ). The
rabbit anti-Amo antiserum has been described.14 Western blot
detection was performed using either an anti-mouse (Dako, Troy,
MI) or anti-rabbit (GE Healthcare, Little Chalfont, UK) horseradish
peroxidase–coupled secondary antibody. For antigen visualization in
immunoﬂuorescence experiments, secondary donkey anti-rabbit
Alexa TM 488 (Invitrogen) antibodies were used.
Cell culture
HeLa and HEK293T cells were cultivated as adherent monolayers in
Dulbecco’s modiﬁed Eagle’s medium (Lonza, Basel, Switzerland)
supplemented with 10% heat-inactivated fetal bovine serum
(Biochrom, Cambridge, UK). Cell lines were maintained in a
humidiﬁed 10% CO2 incubator at 36.5
C. Cells were passaged every
3 to 4 days, using 0.05% trypsin-EDTA (Gibco, Thermo Fisher
Scientiﬁc, Waltham, MA). HeLa and HEK293T cells were transfected
using Lipofectamine 2000 (Invitrogen) and calcium phosphate,
respectively.
Protein isolation
Transiently transfected cells were harvested 24 hours after trans-
fection, if not otherwise stated. Samples were lysed in ice-cold IP
buffer (1% Triton X-100, 20 mM Tris-HCl at pH 7.5, 50 mM NaCl,
50 mM NaF, 15 mM Na4P2O7, 0.1 mM EDTA at pH 8) supple-
mented with 2 mM Na3VO4 and Complete Protease Inhibitor
Cocktail (Roche, Basel, Switzerland). Lysates were ﬁrst centrifuged
at 4 C for 15 minutes at 20,000g and subsequently subjected to
ultracentrifugation at 4 C for 30 minutes at 100,000g. Supernatants
were denatured 30 minutes at 42 C with 2 Laemmli sample buffer
and 100 mM dithiothreitol.
SDS-PAGE, Western blot, and charge-coupled device
camera-based enhanced chemiluminescence detection
Protein samples (about 20 mg of total protein for cell lysates)
were separated by sodium dodecylsulfate–polyacrylamide gel953
t e chn i ca l no te s A Hofherr et al.: Small-molecule rescue of a PKD2 mutationelectrophoresis (SDS-PAGE) using Mini-PROTEAN TGX 4–15%
precast gels (Bio-Rad Laboratories Inc., Hercules, CA). Proteins were
Western blotted semi-dry on Immobilon-P PVDF (Millipore, Bill-
erica, MA). Membranes were blocked with 5% bovine serum albu-
min (SERVA, Heidelberg, Germany) and probed with antibodies
diluted in phosphate-buffered saline (Biochrom): anti-TRPP2698–799,
1:400; Anti-b-Actin, 1:5000; anti-ubiquitin, 1:1000; anti-a-tubulin,
1:80; or anti-Amo, 1:1000. Immobilized antigens conjugated to
horseradish peroxidase–labeled antibodies were detected using
SuperSignal West Pico chemiluminescent substrate (Thermo Fisher
Scientiﬁc). A 16-bit ChemoCam (Intas Science Imaging Instruments,
Göttingen, Germany) was used for light detection; images were taken
within the dynamic range of the charge-coupled device sensor. None
of the depicted bands is saturated.
RNA isolation, reverse transcriptase polymerase chain
reaction, and real-time quantitative polymerase
chain reaction
RNA of transiently transfected HeLa cells was isolated (RNeasy Plus
Mini Kit, Qiagen, Hilden, Germany) and retrotranscribed to cDNA
(QuantiTect, Qiagen) according to the manufacturer’s protocols.
Subsequently, quantitative polymerase chain reaction (LightCycler
480 SYBR Green I Master, Roche) was performed using the
following oligonucleotides: (i) human PKD2, 50-AGCGGACATA-
GCTCCAGAAGGAG and 50-GATGGAATGCTCCATCCGGTC; and
(ii) human HSPCB, 50-TCTGGGTATCGGAAAGCAAGCC and
50-GTGCACTTCCTCAGGCATCTTG. Samples were analyzed on a
LightCycler 480 (Roche) and relative quantiﬁcation was calculated:
R ¼ 2–(DCP PKD2 – DCP HSPCB).23
Temperature assay and small-molecule inhibitors
Protein stability at low temperature was assessed after transfected
HeLa cells were cultivated for 2 days at 27 C (humidiﬁed 10% CO2
incubator). Drug incubation of HeLa cells was started 24 hours after
transfection. Small-molecule inhibitors were added to Dulbecco’s
modiﬁed Eagle’s medium (Lonza) supplemented with 10% heat-
inactivated fetal bovine serum (Biochrom); cells were maintained
in a humidiﬁed 10% CO2 incubator at 36.5
C. Drug concentrations
and incubation times were: 200 mM chloroquine (Sigma-Aldrich) for
24 hours; and 210 mM MG-132 (Enzo Life Sciences, Ann Arbor, MI)
for 6 hours. Cells were counted after harvesting using a TC10
automated cell counter (Bio-Rad). Sample volume was normalized
for cell count.
Flies, husbandry, and drug treatments
All ﬂies were reared according to standard procedures and main-
tained at 25 C. Amo mutant ﬂies (amo, amo–/–;amo, and
amo–/–;amoD627V) have been described.8,14 Brieﬂy, transgenic ﬂies
expressing wild-type and mutant Amo (D627V) were generated
using site-speciﬁc recombination with an attP landing site on the
third chromosome.8 w1118 ﬂies served as wild-type controls. Chlo-
roquine (0.2 mM or 3 mM) was added to Nutri-Fly Instant White
(Genesee Scientiﬁc, San Diego, CA). Using these media, ﬂies were
cultured at 25 C, and male offspring was collected for fertility tests,
immunoﬂuorescence, or protein biochemistry.
Fertility assays
D melanogaster males of various genotypes were separated upon
eclosion and maintained in isolation 2 days prior to mating. Double
pair matings with w1118 virgin females were performed for 5 days. At954that time both parents were removed from the vial. The number of
progeny that eclosed from each vial was counted.
Immunoﬂuorescence of D melanogaster sperm
Dissection and preparation of testis and spermatozoa as well as
the anti-Amo antiserum have been described.14 Microscopy images
were recorded using a Zeiss Axio Observer microscope (Zeiss,
Oberkochen, Germany).
Protein isolation of D melanogaster
For each experiment, 37 freshly eclosed w1118, amo–/–;amoD627V, and
chloroquine-treated (3 mM) amo–/–;amoD627V male ﬂies were
collected. Whole ﬂies were lysed and Amo protein precipitated using
the Pierce Co-Immunoprecipitation Kit (Thermo Fisher Scientiﬁc)
with 10 ml anti-Amo antiserum14 according to the manufacturer’s
protocol. Samples were analyzed by SDS-PAGE and Western blotting
as described above. Membranes were probed with anti-Amo anti-
serum14 diluted 1:400 in PBS (Biochrom). Super RX ﬁlm (Fujiﬁlm,
Tokyo, Japan) was used for chemiluminescence detection. Images
were developed using a Curix 40 processor (AGFA HealthCare,
Mortsel, Belgium). Amo protein is expressed at rather low levels and
was not detectable in lysates. Detection of Amo on Western blots
required enrichment of the protein using immunoprecipitation.
Statistical analysis
For data quantitation at least 3 independent experiments were
evaluated. Samples were normalized for b-Actin Western blot signals.
Relative expression was calculated for samples on the same gel.
Western blot signal intensities were measured using ImageJ. Student’s
t-test was performed to assess statistical signiﬁcance. D melanogaster
fertility tests were evaluated using the Mann–Whitney U test. An
asterisk indicates P # 0.05.DISCLOSURE
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